IV and Oral Iron Drugs Market, By Route of Administration (Oral Iron Drugs and IV Iron Drugs), By Application (Nephrology, Obstetrics & Gynecology (OBGYN), Cardiac & Thoracic Surgeries, Surgeries, Gastroenterology, Oncology, and Heart Failure), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI384220 | Publish Date: August 2023 | No. of Pages: 178

Global IV And Oral Iron Overview

Introduction:

Iron is a vital component for all living organisms as they are essential for the smooth functioning of various metabolic processes that includes oxygen transport, electron transport and DNA synthesis. Moreover, iron is included in the production of erythrocytes (RBCs) that transport oxygen in the blood. The lack of proper levels of iron or decreased total iron contents in the body is called as iron deficiency (ID). Absence of adequate iron levels will decrease the production of RBCs in the body, therefore, affecting the transport of oxygen to different parts of the body.IV and Oral Iron Drugs Market accounted for US$ 1.6 billion in 2020 and is estimated to be US$ 3.3 billion by 2030 and is anticipated to register a CAGR of 7.5%

Drivers and Restraints:

The increase in the population of the iron deficiency leads to highly prevalent nutritional disorders and around 1/4th population is affected globally which is the major driving factor for the growth of the global market. As per the World Health Organization (WHO), effective and timely treatment of ID can raise both national productivity levels by as much as 20% and also rise in restore personal health. Additionally, the increase in demand for non-dextran IV iron therapeutics for the treatment of iron deficiency is the propelling factor for the growth of the target market. Moreover, increasing demand among the patients of dialysis and non-dialysis patients is another fueling factor for the growth of the global market. However, the availability of alternative for the IV & oral drugs in the low cost is the major restraining factor for the growth of the global IV and oral iron drugs market. Nevertheless, the rise in strategic licensing and collaborations can create a lucrative opportunity for the growth of the target market.

Segmentation:

The global IV and oral iron drugs market is segmented based on the route of administration, application, and region.

Based on the route of administration, the global IV and oral iron drugs market is segmented into the oral iron drugs and IV iron drugs. IV iron drugs are the dominating drugs for the route of administration segments due to the fast and timely effect of IV iron drugs. Based on application, the target market is bifurcated into nephrology, obstetrics & gynaecology (OBGYN), cardiac & thoracic surgeries, surgeries, gastroenterology, oncology, and heart failure.

Based on the region the global IV and oral iron drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounts highest revenue share to the global IV and oral iron drugs market due to the growing population of iron deficiency and rise in the geriatric population. Europe is anticipant to witness significate growth in the target market due to increasing demand for the IV and oral iron drugs over the forecast period.

Key Players:                                                                                                  

The key players operating the global IV and oral iron drugs market involves VIFOR Pharma Group, Daiichi Sankyo Company, Amag Pharmaceuticals, Akebia Therapeutics, Shield Therapeutics, Pharmacosmos, Allergan, Sunny Pharmaceutical, AOP Orphan Pharmaceuticals, and Salveo Lifecare. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the route of administrations to gain a competitive edge in the target market. For instance, in 2018, Shield Therapeutics signed an agreement with Norgine for the product Feraccru. Due to this agreement, Norgine received right for the commercialization for Feraccru from the Shield Therapeutics.

Detailed Segmentation:

Global IV and Oral Iron Drugs Market, By Route of Administration:

  • Oral Iron Drugs
  • IV Iron Drugs

Global IV and Oral Iron Drugs Market, By Application:

  • Nephrology
  • Obstetrics & Gynecology (OBGYN)
  • Cardiac & Thoracic Surgeries
  • Surgeries
  • Gastroenterology
  • Oncology
  • Heart Failure

Global IV and Oral Iron Drugs Market, By Region:

      • North America
        • North America IV and Oral Iron Drugs Market, By Route of Administration
        • North America IV and Oral Iron Drugs Market, By Application
        • North America IV and Oral Iron Drugs Market, By Country
          • The U.S.
          • Canada
      • Europe
        • Europe IV and Oral Iron Drugs Market, By Route of Administration
        • Europe IV and Oral Iron Drugs Market, By Application
        • Europe IV and Oral Iron Drugs Market, By Country
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
        • Asia Pacific IV and Oral Iron Drugs Market, By Route of Administration
        • Asia Pacific IV and Oral Iron Drugs Market, By Application
        • Asia Pacific IV and Oral Iron Drugs Market, By Country
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
        • Latin America IV and Oral Iron Drugs Market, By Route of Administration
        • Latin America IV and Oral Iron Drugs Market, By Application
        • Latin America IV and Oral Iron Drugs Market, By Country
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
        • Middle East & Africa IV and Oral Iron Drugs Market, By Route of Administration
        • Middle East & Africa IV and Oral Iron Drugs Market, By Application
        • Middle East & Africa IV and Oral Iron Drugs Market, By Country
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Company Profile:

  • VIFOR Pharma Group
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Daiichi Sankyo Company
  • Amag Pharmaceuticals
  • Akebia Therapeutics
  • Shield Therapeutics
  • Pharmacosmos
  • Allergan  
  • Sunny Pharmaceutical
  • AOP Orphan Pharmaceuticals
  • Salveo Lifecare

 “*” marked represents similar segmentation in other categories in the respective section

Key Issues Addressed

  • What is the total revenue potential of the global IV and oral iron drugs market? How that market is expected to grow during the study period?
  • What are some of the major growth opportunities in the IV and oral iron drugs market?
  • Which companies are the major players in the IV and oral iron drugs market?

Global IV And Oral Iron Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Industry Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for IV and Oral Iron Drugs Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Route of Administration
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global IV and Oral Iron Drugs Market, By Route of Administration, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Oral Iron Drugs
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • IV Iron Drugs
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global IV and Oral Iron Drugs Market, By Application, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Nephrology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Obstetrics & Gynaecology (OBGYN)
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Cardiac & Thoracic Surgeries
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Surgeries
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Gastroenterology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Oncology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Heart Failure
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global IV and Oral Iron Drugs Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  9. Company Profiles
    • VIFOR Pharma Group
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Daiichi Sankyo Company
    • Amag Pharmaceuticals
    • Akebia Therapeutics
    • Shield Therapeutics
    • Pharmacosmos
    • Allergan
    • Sunny Pharmaceutical
    • AOP Orphan Pharmaceuticals
    • Salveo Lifecare
  10. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The IV and Oral Iron Drugs Market accounted for US$ 1.6 billion in 2020 and is estimated to be US$ 3.3 billion by 2030 and is anticipated to register a CAGR of 7.5%.

The IV and oral iron drugs market is segmented based on the route of administration, application, and region.

the development of innovative iron formulations, the focus on patient-friendly iron supplementation, and advancements in iron deficiency management, presenting significant opportunities in the global IV and Oral Iron Drugs Market.

high prevalence of iron deficiency disorders, advancements in iron drug delivery technologies, the growing awareness of the importance of iron supplementation, and the rising demand for effective and well-tolerated iron therapies.

North America and Europe are expected to dominate the IV and Oral Iron Drugs Market, driven by a high prevalence of iron deficiency, well-established healthcare systems, and significant market presence of key players in these regions.

The key players operating the global IV and oral iron drugs market involves VIFOR Pharma Group, Daiichi Sankyo Company, Amag Pharmaceuticals, Akebia Therapeutics, Shield Therapeutics, Pharmacosmos, Allergan, Sunny Pharmaceutical, AOP Orphan Pharmaceuticals, and Salveo Lifecare.